<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Optimal reexpression of most genes silenced through promoter methylation requires the sequential application of DNA methyltransferase inhibitors followed by <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase inhibitors in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> cell cultures </plain></SENT>
<SENT sid="1" pm="."><plain>Patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) were treated with the methyltransferase inhibitor 5-<z:chebi fb="0" ids="2038">azacitidine</z:chebi> (aza-CR) followed by the <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase inhibitor <z:chebi fb="199" ids="26708">sodium</z:chebi> phenylbutyrate </plain></SENT>
<SENT sid="2" pm="."><plain>Major responses associated with cytogenetic complete response developed in patients receiving prolonged dosing schedules of aza-CR </plain></SENT>
<SENT sid="3" pm="."><plain><z:chebi fb="0" ids="17137">Bisulfite</z:chebi> sequencing of the p15 promoter in marrow DNA during the first cycle of treatment showed <z:hpo ids='HP_0001425'>heterogeneous</z:hpo> allelic demethylation in three responding patients, suggesting ongoing demethylation within the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> clone, but no demethylation in two nonresponders </plain></SENT>
<SENT sid="4" pm="."><plain>Six of six responding patients with pretreatment methylation of p15 or CDH-1 promoters reversed methylation during the first cycle of therapy (methylation-specific PCR), whereas none of six nonresponders showed any demethylation </plain></SENT>
<SENT sid="5" pm="."><plain>Gene demethylation correlated with the area under the aza-CR plasma concentration-time curve </plain></SENT>
<SENT sid="6" pm="."><plain>Administration of both drugs was associated with induction of acetylation of <z:chebi fb="0" ids="15358">histones</z:chebi> H3 and H4 </plain></SENT>
<SENT sid="7" pm="."><plain>This study provides the first demonstration that molecular mechanisms responsible for responses to DNA methyltransferase/<z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase inhibitor combinations may include reversal of aberrant epigenetic gene silencing </plain></SENT>
<SENT sid="8" pm="."><plain>The promising percentage of major hematologic responses justifies the testing of such combinations in prospective randomized trials </plain></SENT>
</text></document>